ATE527349T1 - Nervenregeneration - Google Patents

Nervenregeneration

Info

Publication number
ATE527349T1
ATE527349T1 AT05762470T AT05762470T ATE527349T1 AT E527349 T1 ATE527349 T1 AT E527349T1 AT 05762470 T AT05762470 T AT 05762470T AT 05762470 T AT05762470 T AT 05762470T AT E527349 T1 ATE527349 T1 AT E527349T1
Authority
AT
Austria
Prior art keywords
nerve
population
dna sequence
area near
cultured cells
Prior art date
Application number
AT05762470T
Other languages
English (en)
Inventor
Chang Kim
Kwan Hee Lee
Original Assignee
Tissuegene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tissuegene Inc filed Critical Tissuegene Inc
Application granted granted Critical
Publication of ATE527349T1 publication Critical patent/ATE527349T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT05762470T 2004-06-23 2005-06-23 Nervenregeneration ATE527349T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58262704P 2004-06-23 2004-06-23
PCT/US2005/021993 WO2006002202A2 (en) 2004-06-23 2005-06-23 Nerve regeneration

Publications (1)

Publication Number Publication Date
ATE527349T1 true ATE527349T1 (de) 2011-10-15

Family

ID=35782307

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05762470T ATE527349T1 (de) 2004-06-23 2005-06-23 Nervenregeneration

Country Status (11)

Country Link
US (2) US20060014288A1 (de)
EP (1) EP1784486B1 (de)
JP (1) JP4576426B2 (de)
KR (1) KR100917403B1 (de)
CN (1) CN101031645B (de)
AT (1) ATE527349T1 (de)
AU (2) AU2005258101B2 (de)
CA (2) CA2571318C (de)
DK (1) DK1784486T3 (de)
ES (1) ES2376332T3 (de)
WO (1) WO2006002202A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
EP1897552B1 (de) 2003-04-18 2009-06-17 Biogen Idec MA Inc. Polymerkonjugiertes glycosiliertes Neublastin
KR20110126732A (ko) * 2004-08-19 2011-11-23 바이오겐 아이덱 엠에이 인코포레이티드 뉴블라스틴 변형체
KR101241551B1 (ko) * 2004-08-19 2013-03-11 바이오겐 아이덱 엠에이 인코포레이티드 전환 성장 인자 베타 패밀리 단백질의 리폴딩
AU2006261889B2 (en) * 2005-06-23 2010-09-30 Kolon Tissuegene, Inc. Neuroprotective effective compound
TWI501774B (zh) * 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
WO2007103182A2 (en) * 2006-03-01 2007-09-13 Biogen Idec Ma Inc. Compostions and methods for administering gdnf ligand family proteins
TWI445544B (zh) * 2007-05-01 2014-07-21 Biogen Idec Inc 增進血管形成之組合物及方法
WO2009020964A2 (en) * 2007-08-08 2009-02-12 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
CA2701757C (en) * 2007-10-12 2016-11-22 Panasonic Corporation Vector quantization apparatus, vector dequantization apparatus and the methods
WO2009110215A1 (ja) * 2008-03-03 2009-09-11 独立行政法人 科学技術振興機構 繊毛細胞の分化誘導方法
WO2013188744A1 (en) * 2012-06-15 2013-12-19 Baylor College Of Medicine Perineurium derived adult stem cells and methods of use
US10595754B2 (en) 2014-03-13 2020-03-24 Sano Intelligence, Inc. System for monitoring body chemistry

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210026A (en) * 1990-08-20 1993-05-11 American Cyanamid Company Human mk gene and method of expression
US6723698B2 (en) * 1991-03-11 2004-04-20 Curis, Inc. Methods and compositions for the treatment of motor neuron injury and neuropathy
DK0653942T3 (da) * 1992-07-31 2003-10-20 Curis Inc Morphogen-induceret nerve-regenerering og -reparation
KR100328752B1 (ko) * 1993-08-26 2002-09-26 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 인간골형태발생단백질을사용한신경재생법
US7011827B2 (en) * 1993-11-09 2006-03-14 Trustees Of The University Of Pennsylvania Compositions and methods for producing and using homogenous neuronal cell transplants
AU4989399A (en) 1998-07-15 2000-02-07 Human Genome Sciences, Inc. Bone morphogenic protein
US6743613B2 (en) * 1999-04-23 2004-06-01 Human Genome Sciences, Inc. Lysyl-oxidase HOHEC84 polynucleotides
AU7355500A (en) * 1999-09-08 2001-04-10 Genetics Institute Inc. Bmp-9 compositions and methods for inducing differentiation of cholinergic neurons
US6696410B1 (en) * 1999-09-27 2004-02-24 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors
CN1319423A (zh) * 2001-02-19 2001-10-31 南通医学院 神经再生素及其生产方法和用途
IL147412A0 (en) * 2001-12-31 2002-08-14 Yeda Res & Dev The use of il6r/il6 chimera in nerve cell regeneration
US20050013870A1 (en) * 2003-07-17 2005-01-20 Toby Freyman Decellularized extracellular matrix of conditioned body tissues and uses thereof
WO2005068498A2 (en) * 2004-01-19 2005-07-28 Nsgene A/S Human therapeutic cells secreting nerve growth factor

Also Published As

Publication number Publication date
CA2571318C (en) 2011-06-07
ES2376332T3 (es) 2012-03-13
AU2009201827A1 (en) 2009-05-28
AU2005258101A1 (en) 2006-01-05
EP1784486A4 (de) 2007-10-17
WO2006002202A2 (en) 2006-01-05
CN101031645A (zh) 2007-09-05
JP2008504269A (ja) 2008-02-14
KR20070039554A (ko) 2007-04-12
CA2571318A1 (en) 2006-01-05
AU2009201827B2 (en) 2013-01-31
CA2735272A1 (en) 2006-01-05
JP4576426B2 (ja) 2010-11-10
CN101031645B (zh) 2011-06-08
WO2006002202A3 (en) 2006-10-12
US20060014288A1 (en) 2006-01-19
US20220241433A1 (en) 2022-08-04
AU2005258101B2 (en) 2009-08-27
EP1784486A2 (de) 2007-05-16
DK1784486T3 (da) 2012-01-16
KR100917403B1 (ko) 2009-09-14
EP1784486B1 (de) 2011-10-05

Similar Documents

Publication Publication Date Title
ATE527349T1 (de) Nervenregeneration
CA2713338C (en) Recombinant virus production using mammalian cells in suspension
ATE412761T1 (de) Methode um rekombinante proteine in cho zellen zu exprimieren
PH12020551039A1 (en) Non-viral dna vectors and uses thereof for antibody and fusion protein production
MX357691B (es) Il-15 y il-15r-alfa mejoradas para expresion en celulas mamiferas.
FI3536797T3 (fi) Siirtogeenin tehostettu ilmentäminen ja prosessointi
DE69922933D1 (de) Anwendungen für humane nicht autologe, mesenchymale stammzellen
AP1678A (en) Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
EP1697521A4 (de) Multiplasmid-system zur erzeugung des grippevirus
FI932678A0 (fi) Pao alfavirus baserande DNA expressionssystem
DK0633929T3 (da) Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
DE69836092D1 (de) Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen
WO2007055823A3 (en) Gpcr expressing cell lines and antibodies
EP1616960A3 (de) Menschliche Pancreas Zellinien: Entwicklungen und Anwendungen
SG163592A1 (en) Methods and compositions for increasing longevity and protein yield from a cell culture
WO2006104609A3 (en) Isolated myeloid-like bone marrow cell populations and methods of treatment therewith
EP1702071A4 (de) Transaktivierungssystem für säugerzellen
ATE464320T1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
WO2004076626A3 (en) Methods of gene therapy for treating disorders of the ear by administering a vector encoding an atonal-associated factor
MX2021011039A (es) Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con fviii.
WO2008070273A3 (en) Methods of expressing lim mineralization protein
DE69635513D1 (de) Menschliche pancreas zellinien: entwicklungen und anwendungen
WO2007002512A3 (en) Neuroprotective effective compound
ATE338826T1 (de) Rekombinante virale vektoren zur tetracyclinregulierbaren genexpression
Bobick et al. High efficiency transfection of embryonic limb mesenchyme with plasmid DNA using square wave pulse electroporation and sucrose buffer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties